Wechselwirkungen von Piroxicam

Piroxicam (Feldene), ein NSAR, hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 256 dokumentierte Wechselwirkungen: 50 schwerwiegende, 197 mittelschwere, 9 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (50)

  • AcetylsalicylsäureNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • Acetylsalicylsäure und DipyridamolThrombozytenaggregationshemmerSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • ApixabanAntikoagulans (Gerinnungshemmer)Schwerwiegend

    …risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (Fachinformation zu Apixaban, Boxed Warning (umrahmter Warnhinweis))

  • BalsalazidSalicylatSchwerwiegend

    Intervention: The concomitant use of piroxicam with other NSAIDs or salicylates is not recommended. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • BismutsubsalicylatSalicylatSchwerwiegend

    Intervention: The concomitant use of piroxicam with other NSAIDs or salicylates is not recommended. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • CelecoxibNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • CidofovirVirostatikumSchwerwiegend

    Nephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated. (Fachinformation zu Cidofovir, Arzneimittelwechselwirkungen)

  • DabigatranAntikoagulans (Gerinnungshemmer)Schwerwiegend

    …the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (Fachinformation zu Dabigatran, Boxed Warning (umrahmter Warnhinweis))

  • DiclofenacNSARSchwerwiegend

    NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • DiflunisalNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • EdoxabanAntikoagulans (Gerinnungshemmer)Schwerwiegend

    …the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (Fachinformation zu Edoxaban, Boxed Warning (umrahmter Warnhinweis))

  • Efavirenz, Lamivudin und Tenofovirantiretrovirales ArzneimittelSchwerwiegend

    Avoid SYMFI with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.3) ] . (Fachinformation zu Efavirenz, Lamivudin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

  • Emtricitabin, Rilpivirin und Tenofovirantiretrovirales ArzneimittelSchwerwiegend

    COMPLERA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.4) ]. (Fachinformation zu Emtricitabin, Rilpivirin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

  • EnoxaparinAntikoagulans (Gerinnungshemmer)Schwerwiegend

    …the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity… (Fachinformation zu Enoxaparin, Boxed Warning (umrahmter Warnhinweis))

  • EtodolacNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • FenoprofenNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • FlurbiprofenNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • FondaparinuxAntikoagulans (Gerinnungshemmer)Schwerwiegend

    …risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity… (Fachinformation zu Fondaparinux, Boxed Warning (umrahmter Warnhinweis))

  • Hydrocodon und IbuprofenOpioidSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • IbuprofenNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • Ibuprofen und FamotidinNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • IndometacinNSARSchwerwiegend

    NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • KetoprofenNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • KetorolacNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • MefenaminsäureNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • MeloxicamNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • Menthol und MethylsalicylatSalicylatSchwerwiegend

    Intervention: The concomitant use of piroxicam with other NSAIDs or salicylates is not recommended. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • MesalazinSalicylatSchwerwiegend

    Intervention: The concomitant use of piroxicam with other NSAIDs or salicylates is not recommended. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • MethotrexatImmunsuppressivumSchwerwiegend

    Unexpectedly severe and fatal gastrointestinal toxicity can occur with concomitant administration of XATMEP (primarily at high dosage) and nonsteroidal anti-inflammatory drugs (NSAIDs) [see Drug Interactions ( 7.1 )] . (Fachinformation zu Methotrexat, Warnhinweise und Vorsichtsmaßnahmen)

  • MisoprostolProstaglandin-AnalogonSchwerwiegend

    MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). (Fachinformation zu Misoprostol, Boxed Warning (umrahmter Warnhinweis))

  • MontelukastLeukotrienrezeptor-AntagonistSchwerwiegend

    Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR ( 5.4 ). (Fachinformation zu Montelukast, Warnhinweise und Vorsichtsmaßnahmen)

  • NabumetonNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • NaproxenNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • Naproxen und EsomeprazolNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • OxaprozinNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • Paracetamol und IbuprofenNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • PemetrexedAntimetabolitSchwerwiegend

    NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • PralatrexatAntimetabolitSchwerwiegend

    Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. (Fachinformation zu Pralatrexat, Arzneimittelwechselwirkungen)

  • PrasugrelThrombozytenaggregationshemmerSchwerwiegend

    Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (e.g . , warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Warnings and Precautions (5.1) ] . (Fachinformation zu Prasugrel, Boxed Warning (umrahmter Warnhinweis))

  • RivaroxabanAntikoagulans (Gerinnungshemmer)Schwerwiegend

    …risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (Fachinformation zu Rivaroxaban, Boxed Warning (umrahmter Warnhinweis))

  • SalsalatNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • SulfasalazinSulfonamidSchwerwiegend

    Intervention: The concomitant use of piroxicam with other NSAIDs or salicylates is not recommended. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • SulindacNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • Sumatriptan und NaproxenTriptanSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

  • Tenofovirantiretrovirales ArzneimittelSchwerwiegend

    VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.1) ] . (Fachinformation zu Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

  • TolmetinNSARSchwerwiegend

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (Fachinformation zu Piroxicam, Gegenanzeigen)

Mittelschwere Wechselwirkungen (197)

  • AcebutololBetablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • AcetazolamidCarboanhydrasehemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • AdefovirVirostatikumMittelschwer

    However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (Fachinformation zu Adefovir, Warnhinweise und Vorsichtsmaßnahmen)

  • AfatinibMittelschwer

    Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (Fachinformation zu Afatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • AlendronsäureBisphosphonatMittelschwer

    Use caution when co-prescribing aspirin/nonsteroidal anti- inflammatory drugs that may worsen gastrointestinal irritation. (Fachinformation zu Alendronsäure, Arzneimittelwechselwirkungen)

  • AliskirenAntihypertensivumMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • AlkoholAlkoholMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • AlprostadilProstaglandin-AnalogonMittelschwer

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Amiloridkaliumsparendes DiuretikumMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • AmlodipinDihydropyridin-CalciumkanalblockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • Amlodipin und AtorvastatinDihydropyridin-CalciumkanalblockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • Amlodipin und BenazeprilDihydropyridin-CalciumkanalblockerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Amlodipin und OlmesartanDihydropyridin-CalciumkanalblockerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Amlodipin und ValsartanDihydropyridin-CalciumkanalblockerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • AnagrelidQT-verlängerndes ArzneimittelMittelschwer

    Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (Fachinformation zu Anagrelid, Warnhinweise und Vorsichtsmaßnahmen)

  • ArgatrobanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • AtenololBetablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • Atenolol und ChlortalidonBetablockerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • AtomoxetinNoradrenalin-WiederaufnahmehemmerMittelschwer

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Azelastin und FluticasonAntihistaminikumMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • AzilsartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • BeclometasonKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • BenazeprilACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Benazepril und HydrochlorothiazidACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • BetamethasonKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • BetaxololBetablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • BimatoprostProstaglandin-AnalogonMittelschwer

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • BisoprololBetablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • Bisoprolol und HydrochlorothiazidBetablockerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • BivalirudinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Brimonidin und TimololAlpha-Adrenozeptor-AgonistMittelschwer

    Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • BudesonidKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Budesonid und FormoterolKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • BumetanidSchleifendiuretikumMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • CandesartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Candesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • CangrelorThrombozytenaggregationshemmerMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • CaptoprilACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • CarboprostProstaglandin-AnalogonMittelschwer

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • CarvedilolBetablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • CefotaximCephalosporinMittelschwer

    Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (Fachinformation zu Cefotaxim, Arzneimittelwechselwirkungen)

  • ChlorothiazidThiaziddiuretikumMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • ChlortalidonThiaziddiuretikumMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • CiclesonidKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • CiclosporinImmunsuppressivumMittelschwer

    Cyclosporine Clinical Impact: Concomitant use of Piroxicam Capsules and cyclosporine may increase cyclosporine's nephrotoxicity. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • CilostazolThrombozytenaggregationshemmerMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • CiprofloxacinFluorchinolonMittelschwer

    NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. (Fachinformation zu Ciprofloxacin, Arzneimittelwechselwirkungen)

  • CitalopramSSRIMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • ClobetasolKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • ClonidinAlpha-Adrenozeptor-AgonistMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • ClopidogrelThrombozytenaggregationshemmerMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • DapagliflozinSGLT-2-HemmerMittelschwer

    …↔ ↔ Valsartan (320 mg) 20 mg ↓12% [↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7% [↓22%, ↑11%] ↓22% [↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13% [↑3%, ↑24%] ↑51% [↑44%, ↑58%] ↔ = no change (geometric… (Fachinformation zu Dapagliflozin, Arzneimittelwechselwirkungen)

  • DeferasiroxEisenpräparatMittelschwer

    The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (Fachinformation zu Deferasirox, Warnhinweise und Vorsichtsmaßnahmen)

  • DeflazacortKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • DesmopressinMittelschwer

    …Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (Fachinformation zu Desmopressin, Arzneimittelwechselwirkungen)

  • DesonidKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • DesvenlafaxinSNRIMittelschwer

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • DexamethasonKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • DigoxinDigitalisglykosidMittelschwer

    Digoxin: Concomitant use of Piroxicam Capsules can increase serum concentration and prolong half-life of digoxin. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • DiltiazemCalciumkanalblockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • DinoprostonProstaglandin-AnalogonMittelschwer

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • DipyridamolThrombozytenaggregationshemmerMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • DonepezilCholinesterasehemmerMittelschwer

    Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (Fachinformation zu Donepezil, Warnhinweise und Vorsichtsmaßnahmen)

  • Dorzolamid und TimololCarboanhydrasehemmerMittelschwer

    Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • DoxazosinAlphablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • Drospirenon und Ethinylestradiolorales KontrazeptivumMittelschwer

    Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (Fachinformation zu Drospirenon und Ethinylestradiol, Warnhinweise und Vorsichtsmaßnahmen)

  • DuloxetinSNRIMittelschwer

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Elvitegravir, Cobicistat, Emtricitabin und Tenofovirantiretrovirales ArzneimittelMittelschwer

    Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (Fachinformation zu Elvitegravir, Cobicistat, Emtricitabin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

  • Emtricitabin und Tenofovirantiretrovirales ArzneimittelMittelschwer

    Individuals taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (Fachinformation zu Emtricitabin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

  • EnalaprilACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Enalapril und HydrochlorothiazidACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • EnalaprilatACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • EplerenonAldosteronantagonistMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • EpoprostenolProstaglandin-AnalogonMittelschwer

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • EptifibatidThrombozytenaggregationshemmerMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • ErlotinibMittelschwer

    Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (Fachinformation zu Erlotinib, Warnhinweise und Vorsichtsmaßnahmen)

  • EscitalopramSSRIMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • EsmololBetablockerMittelschwer

    Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • EtacrynsäureSchleifendiuretikumMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • FebuxostatXanthinoxidasehemmerMittelschwer

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Fachinformation zu Febuxostat, Warnhinweise und Vorsichtsmaßnahmen)

  • FelodipinDihydropyridin-CalciumkanalblockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • FluconazolAzol-AntimykotikumMittelschwer

    Non-steroidal anti-inflammatory drugs The C max and AUC of flurbiprofen were increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen alone. (Fachinformation zu Fluconazol, Arzneimittelwechselwirkungen)

  • FludrocortisonKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • FlunisolidKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • FluocinonidKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • FluoxetinSSRIMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • FluticasonKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Fluticason und SalmeterolKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • FluvoxaminSSRIMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • FosinoprilACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Fosinopril und HydrochlorothiazidACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • FurosemidSchleifendiuretikumMittelschwer

    Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • GalantaminCholinesterasehemmerMittelschwer

    Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Fachinformation zu Galantamin, Warnhinweise und Vorsichtsmaßnahmen)

  • GlibenclamidSulfonylharnstoffMittelschwer

    Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking… (Fachinformation zu Glibenclamid, Arzneimittelwechselwirkungen)

  • GlimepiridSulfonylharnstoffMittelschwer

    …steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

  • GlipizidSulfonylharnstoffMittelschwer

    …angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor antagonists, and quinolones. (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

  • Glipizid und MetforminSulfonylharnstoffMittelschwer

    Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (Fachinformation zu Glipizid und Metformin, Vorsichtsmaßnahmen)

  • GuanfacinAlpha-Adrenozeptor-AgonistMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • HalobetasolKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • HeparinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • HydralazinVasodilatatorMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • HydrochlorothiazidThiaziddiuretikumMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • HydrocortisonKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • IbandronsäureBisphosphonatMittelschwer

    Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (Fachinformation zu Ibandronsäure, Arzneimittelwechselwirkungen)

  • IndapamidThiaziddiuretikumMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • IrbesartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Irbesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • IsradipinDihydropyridin-CalciumkanalblockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • ItraconazolAzol-AntimykotikumMittelschwer

    Nonsteroidal Anti-Inflammatory Drugs Meloxicam Concomitant drug dose increase may be necessary. (Fachinformation zu Itraconazol, Arzneimittelwechselwirkungen)

  • KaliumchloridKaliumpräparatMittelschwer

    Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

  • KaliumcitratKaliumpräparatMittelschwer

    Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) (Fachinformation zu Kaliumcitrat, Arzneimittelwechselwirkungen)

  • LabetalolBetablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • LatanoprostProstaglandin-AnalogonMittelschwer

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • LevofloxacinFluorchinolonMittelschwer

    Non-Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including Levofloxacin in 5% Dextrose Injection, may increase the risk of CNS stimulation and convulsive seizures [see Warnings and Precautions (5.4) ]. (Fachinformation zu Levofloxacin, Arzneimittelwechselwirkungen)

  • LevomilnacipranSNRIMittelschwer

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • LisinoprilACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Lisinopril und HydrochlorothiazidACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Lithiumserotonerges ArzneimittelMittelschwer

    Lithium Clinical Impact: NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • LofexidinAlpha-Adrenozeptor-AgonistMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • LosartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Losartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • MecamylaminAntihypertensivumMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • Memantin und DonepezilCholinesterasehemmerMittelschwer

    Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (Fachinformation zu Memantin und Donepezil, Warnhinweise und Vorsichtsmaßnahmen)

  • MethyldopaAntihypertensivumMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • MethylprednisolonKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • MetolazonThiaziddiuretikumMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • MetoprololBetablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • Metoprolol und HydrochlorothiazidBetablockerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • MifepristonCYP3A4-HemmerMittelschwer

    When given concomitantly with mifepristone, drugs that are substrates of CYP2C8/2C9 (including non-steroidal anti-inflammatory drugs, warfarin, and repaglinide) should be used at the smallest recommended doses, and patients should be closely monitored for adverse effects. [See Clinical Pharmacology ( 12.3 )] 7.5 Drugs Metabolized by CYP2B6 Mifepristone is an… (Fachinformation zu Mifepriston, Arzneimittelwechselwirkungen)

  • MilnacipranSNRIMittelschwer

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • MinoxidilVasodilatatorMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • MoexiprilACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • MometasonKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • MoxifloxacinFluorchinolonMittelschwer

    Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Although not observed with moxifloxacin in preclinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions [see Warnings and Precautions ( 5.4 ), and Patient Counseling Information ( 17 )]. (Fachinformation zu Moxifloxacin, Arzneimittelwechselwirkungen)

  • NadololBetablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • NateglinidGlinidMittelschwer

    Table 2: Clinically Significant Drug Interactions with Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone),… (Fachinformation zu Nateglinid, Arzneimittelwechselwirkungen)

  • NebivololBetablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • NicardipinDihydropyridin-CalciumkanalblockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • NifedipinDihydropyridin-CalciumkanalblockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • NintedanibMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • NisoldipinDihydropyridin-CalciumkanalblockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • NitroprussidnatriumVasodilatatorMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • OfloxacinFluorchinolonMittelschwer

    Non Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a quinolone, including ofloxacin, may increase the risk of CNS stimulation and convulsive seizures (see WARNINGS and PRECAUTIONS , General ). (Fachinformation zu Ofloxacin, Arzneimittelwechselwirkungen)

  • Olanzapin und FluoxetinAntipsychotikumMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • OlmesartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Olmesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Olmesartan, Amlodipin und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Olopatadin und MometasonAntihistaminikumMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • ParoxetinSSRIMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • PentoxifyllinMethylxanthinMittelschwer

    DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (Fachinformation zu Pentoxifyllin, Arzneimittelwechselwirkungen)

  • PerindoprilACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • PhenoxybenzaminAlphablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • PindololBetablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • Pioglitazon und GlimepiridThiazolidindion (Glitazon)Mittelschwer

    …steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

  • PrazosinAlphablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • PrednisolonKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisonKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • PropranololBetablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • QuinaprilACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Quinapril und HydrochlorothiazidACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • RamiprilACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • RivastigminCholinesterasehemmerMittelschwer

    Monitor patients using rivastigmine tartrate for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (Fachinformation zu Rivastigmin, Warnhinweise und Vorsichtsmaßnahmen)

  • Sacubitril und ValsartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • SertralinSSRIMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • SolriamfetolZNS-StimulansMittelschwer

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • SotalolBetablockerMittelschwer

    Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • SpironolactonAldosteronantagonistMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Spironolacton und HydrochlorothiazidAldosteronantagonistMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Tabak und RauchenTabak und CannabisMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • TelmisartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Telmisartan und AmlodipinAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Telmisartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • TerazosinAlphablockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • TicagrelorThrombozytenaggregationshemmerMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • TimololBetablockerMittelschwer

    Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • TirofibanThrombozytenaggregationshemmerMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • TizanidinMuskelrelaxansMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • TofacitinibImmunsuppressivumMittelschwer

    Promptly evaluate patients treated with XELJANZ/XELJANZ XR who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs) and who present with new onset abdominal symptoms for early identification of gastrointestinal perforation [see Adverse Reactions (6.1) ] . (Fachinformation zu Tofacitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • TorasemidSchleifendiuretikumMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • TrandolaprilACE-HemmerMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • TrazodonAntidepressivumMittelschwer

    Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Trazodon, Warnhinweise und Vorsichtsmaßnahmen)

  • TreprostinilProstaglandin-AnalogonMittelschwer

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • TriamcinolonKortikosteroidMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Triamterenkaliumsparendes DiuretikumMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Triamteren und Hydrochlorothiazidkaliumsparendes DiuretikumMittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • UpadacitinibImmunsuppressivumMittelschwer

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Fachinformation zu Upadacitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • ValsartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • Valsartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • VenlafaxinSNRIMittelschwer

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • VerapamilCalciumkanalblockerMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • VilazodonSSRIMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • ViloxazinNoradrenalin-WiederaufnahmehemmerMittelschwer

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • VoriconazolAzol-AntimykotikumMittelschwer

    NSAIDs Non-Steroidal Anti-Inflammatory Drug including. ibuprofen and diclofenac (CYP2C9 Inhibition) Increased Frequent monitoring for adverse reactions and toxicity related to NSAIDs. (Fachinformation zu Voriconazol, Arzneimittelwechselwirkungen)

  • VortioxetinAntidepressivumMittelschwer

    • Increased Risk of Bleeding : Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, or other drugs that affect coagulation may increase risk ( 5.3 ). (Fachinformation zu Vortioxetin, Warnhinweise und Vorsichtsmaßnahmen)

  • WarfarinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Drugs that Interfere with Hemostasis (e.g. warfarin, aspirin, selective serotonin reuptake inhibitors [SSRIs]/serotonin norepinephrine reuptake inhibitors [SNRIs]): Monitor patients for bleeding who are concomitantly taking Piroxicam Capsules with drugs that interfere with hemostasis. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • ZoledronsäureBisphosphonatMittelschwer

    Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (Fachinformation zu Zoledronsäure, Arzneimittelwechselwirkungen)

Geringfügige Erwähnungen (9)

  • Finasterid5-Alpha-ReduktasehemmerGeringfügig

    …angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions. (Fachinformation zu Finasterid, Arzneimittelwechselwirkungen)

  • Glibenclamid und MetforminSulfonylharnstoffGeringfügig

    Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (Fachinformation zu Glibenclamid und Metformin, Arzneimittelwechselwirkungen)

  • InfliximabImmunsuppressivumGeringfügig

    In RA, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics. (Fachinformation zu Infliximab, Arzneimittelwechselwirkungen)

  • LenalidomidGeringfügig

    Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (Fachinformation zu Lenalidomid, Warnhinweise und Vorsichtsmaßnahmen)

  • LevothyroxinSchilddrüsenhormonGeringfügig

    Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-Inflammatory Drugs - Fenamates These drugs may cause protein-binding site displacement. (Fachinformation zu Levothyroxin, Arzneimittelwechselwirkungen)

  • LiothyroninSchilddrüsenhormonGeringfügig

    Other drugs: Carbamazepine Furosemide (>80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs Fenamates These drugs may cause protein binding site displacement. (Fachinformation zu Liothyronin, Arzneimittelwechselwirkungen)

  • RepaglinidGlinidGeringfügig

    Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

  • RisedronsäureBisphosphonatGeringfügig

    Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (Fachinformation zu Risedronsäure, Arzneimittelwechselwirkungen)

  • TocilizumabImmunsuppressivumGeringfügig

    Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (Fachinformation zu Tocilizumab, Arzneimittelwechselwirkungen)

Prüfen Sie Piroxicam gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.